Comparison of glycated albumin and hemoglobin A1c levels in diabetic subjects on hemodialysis

Kidney International

Volumn 73, Issue 9, 2008, Pages 1062-1068

  Peacock, T P ^a   Shihabi, Z K ^a   Bleyer, A J ^a   Dolbare, E L ^a   Byers, J R ^a   Knovich, M A ^a   Calles Escandon, J ^a   Russell, G B ^a   Freedman, B I ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

Diabetes mellitus; End stage renal disease; Glycated albumin; Glycemic control; Hemodialysis; Hemoglobin A1c

Indexed keywords

ANTIDIABETIC AGENT; ERYTHROPOIETIN; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C; INSULIN; SERUM ALBUMIN;

ADULT; AGED; ANEMIA; ARTICLE; BLOOD SAMPLING; CELL SURVIVAL; CHRONIC KIDNEY DISEASE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DIABETES MELLITUS; DOSE RESPONSE; DRUG MEGADOSE; ERYTHROCYTE LIFESPAN; ETHNICITY; FEMALE; GLUCOSE BLOOD LEVEL; HEMODIALYSIS; HORMONE ACTION; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY DISEASE; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTIVARIATE ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; STATISTICAL ANALYSIS;

EID: 42149123415     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2008.25     Document Type: Article

References (21)

1. Borch-Johnsen K. The metabolic syndrome in a global perspective. The public health impact - secondary publication. Dan Med Bull 2007; 54: 157-159.
2. US Renal Data System. USRDS 2006 Annual Data Report. Atlas of end-stage renal disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases: Bethesda, MD, 2006.
3. Calisti L, Tognetti S. Measure of glycosylated hemoglobin. Acta Biomed 2005; 76(Suppl 3): 59-62.
4. Goldstein DE, Little RR, Lorenz RA et al. Tests of glycemia in diabetes. Diabetes Care 2004; 27: 1761-1773.
5. Ly J, Marticorena R, Donnelly S. Red blood cell survival in chronic renal failure. Am J Kidney Dis 2004; 44: 715-719.
6. Tzamaloukas AH, Hsi KC, Quintana BJ et al. Glycosylated hemoglobin measured by affinity chromatography in diabetic and nondiabetic patients on long-term dialysis therapy. West J Med 1989; 150: 415-419.
7. Joy MS, Cefalu WT, Hogan SL et al. Long-term glycemic control measurements in diabetic patients receiving hemodialysis. Am J Kidney Dis 2002; 39: 297-307.
8. Inaba M, Okuno S, Kumeda Y et al. Glycated albumin is a better glycemic indicator than glycated hemoglobin values in hemodialysis patients with diabetes: effect of anemia and erythropoietin injection. J Am Soc Nephrol 2007; 18: 896-903.
9. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. N Engl J Med 2000; 342: 381-389.
10. Adler AI, Stevens RJ, Manley SE et al. Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int 2003; 63: 225-232.
11. Oomichi T, Emoto M, Tabata T et al. Impact of glycemic control on survival of diabetic patients on chronic regular hemodialysis: a 7-year observational study. Diabetes Care 2006; 29: 1496-1500.
12. Kalantar-Zadeh K, Kopple JD, Regidor DL et al. A1C and survival in maintenance hemodialysis patients. Diabetes Care 2007; 30: 1049-1055.
13. Lin-Tan DT, Lin JL, Wang LH et al. Fasting glucose levels in predicting 1-year all-cause mortality in patients who do not have diabetes and are on maintenance hemodialysis. J Am Soc Nephrol 2007; 18: 2385-2391.
14. Schwartz AB, Kelch B, Terzian L et al. One year of rHuEPO therapy prolongs RBC survival and may stabilize RBC membranes despite natural progression of chronic renal failure to uremia and need for dialysis. ASAIO Trans 1990; 36: M691-M696.
15. Polenakovic M, Sikole A. Is erythropoietin a survival factor for red blood cells? J Am Soc Nephrol 1996; 7: 1178-1182.
16. Koga M, Otsuki M, Matsumoto S et al. Negative association of obesity and its related chronic inflammation with serum glycated albumin but not glycated hemoglobin levels. Clin Chim Acta 2007; 378: 48-52.
17. Miyashita Y, Nishimura R, Morimoto A et al. Glycated albumin is low in obese, type 2 diabetic patients. Diabetes Res Clin Pract 2007; 78: 51-55.
18. Kouzuma T, Uemastu Y, Usami T et al. Study of glycated amino acid elimination reaction for an improved enzymatic glycated albumin measurement method. Clin Chim Acta 2004; 346: 135-143.
19. Clase CM, St Pierre MW, Churchill DN. Conversion between bromcresol green- and bromcresol purple-measured albumin in renal disease. Nephrol Dial Transplant 2001; 16: 1925-1929.
20. Pu LJ, Lu L, Shen WF et al. Increased serum glycated albumin level is associated with the presence and severity of coronary artery disease in type 2 diabetic patients. Circ J 2007; 71: 1067-1073.
21. Okada T, Nakao T, Matsumoto H et al. Association between markers of glycemic control, cardiovascular complications and survival in type 2 diabetic patients with end-stage renal disease. Intern Med 2007; 46: 807-814.